Nova- and decapeptides in the preparation of a drug for the treatment of aids
AssigneeAsta Medica Aktiengesellschaft
InventorsJurgen Engel, Bernhard Kutscher, Michael Bernd, Ulf Niemeyer
Life of this patent
Estimating the term…
Abstract
Described are LHRH-antagonistic and bombesin-antagonistic nona- and decapeptides suitable for use in the preparation of a drug for the treatment of AIDS and ARC as well as for use in the preparation of an immunostimulation drug.
Claims24
A method of combating a virus that causes a disease selected from the group consisting of AIDS and AIDS related complex (ARC) by administering a pharmaceutically effective amount of at least one peptide with an amino acid sequence according to the general Formula I
- Ac-D-Nal(2)-D-Phe(4-Cl)-xxx-A-B-yyy-zzz-Arg-C-D-Ala-NH.sub.2
- wherein
- ______________________________________ xxx = D-Pal(3), [D-phe(4-Cl),] or D-Trp yyy = D-Cit, D-Lys(R), [D-Arg] or D-Hci R is selected from the group consisting of C.sub.1 -C.sub.4)-acyl and (C.sub.1 -C.sub.10-)-alkyl, zzz = L-Leu, Nle, Nva, or t-Leu A = Ser, Ser(sugar) wherein sugar is selected from the group consisting of glucose, galactose, allose, altrose, manose, gulose, idose and talose. B = Tyr, Lys(Nic), or Mop C = Pro, or Ala ______________________________________
- or a pharmaceutically acceptable salt thereof optionally inlcuding hydrochloride, trifluoroacetate, acetate, sulfate, phosphate, mesylate or tosylate.
A method of combating a virus that causes a disease selected from the group consisting of AIDS and ARC by administering a pharmaceutically effective amount of at least one peptide with an amino acid sequence according to Formula II
- [AC-D-Nal(2).sup.1, D-Phe(4-Cl).sup.2, D-Pal(3).sup.3, D-Cit.sup.6, Nle.sup.7, Pro.sup.9, D-Ala.sup.10 ]-LHRH
- or a pharmaceutically acceptable salt thereof.
A method of combating a virus that causes a disease selected from the group consisting of AIDS and ARC by administering a pharmaceutically effective amount of at least one peptide with an amino acid sequence according to Formula III
- [AC-D-Nal(2).sup.1, D-Phe(4-Cl).sup.2, D-Pal(3).sup.3, D-Cit.sup.6, Nva.sup.7, Pro.sup.9, D-Ala.sup.10 ]-LHRH
- or a pharmaceutically acceptable salt thereof.
A method of combating a virus that causes a disease selected from the group consisting of AIDS and ARC by administering a pharmaceutically effective amount of at least one peptide with an amino acid sequence according to Formula IV
- [AC-D-Nal(2).sup.1, D-Phe(4-Cl).sup.2, D-Trp.sup.3, D-Cit.sup.6, Pro.sup.9, D-Ala.sup.10 ]-LHRH
- or a pharmaceutically acceptable salt thereof.
A method of combating a virus that causes a disease selected from the group consisting of AIDS and ARC by administering a pharmaceutically effective amount of at least one peptide with an amino acid sequence according to Formula V
- [AC-D-Nal(2).sup.1, D-Phe(4-Cl).sup.2, D-Pal(3).sup.3, D-Cit.sup.6, Pro.sup.9, D-Ala.sup.10 ]-LHRH
- or a pharmaceutically acceptable salt thereof.
A method of combating a virus that causes a disease selected from the group consisting of AIDS and ARC by administering a pharmaceutically effective amount of at least one peptide with an amino acid sequence according to Formula VI
- [Ac-D-Nal(2).sup.1, D-Phe(4-Cl).sup.2, D-Pal(3).sup.3, D-Hci.sup.6, Pro.sup.9, D-Ala.sup.10 ]-LHRH
- or a pharmaceutically acceptable salt thereof.
A method of combating a virus that causes a disease selected from the group consisting of AIDS and ARC by administering a pharmaceutically effective amount of at least one peptide with an amino acid sequence according to Formula VII
- [Ac-D-Nal(2).sup.1, D-Phe(4-Cl).sup.2, D-Pal(3).sup.3, D-Cit.sup.8, t-Leu.sup.7, Pro.sup.9, D-Ala.sup.10 ]-LHRH
- or a pharmaceutically acceptable salt thereof.
A method of combating a virus that causes a disease selected from the group consisting of AIDS and ARC by administering a pharmaceutically effective amount of at least one peptide with an amino acid sequence according to Formula VII
- [Ac-D-Nal(2).sup.1, D-Phe(4-Cl).sup.2, D-Pal(3).sup.3, D-Cit.sup.6, Ala.sup.9, D-Ala.sup.10 ]-LHRH
- or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.